share_log

华海药业(600521.SH):二甲双胍恩格列净片(I)获得药品注册证书

Zhejiang Huahai Pharmaceutical (600521.SH): Metformin and Ertugliflozin Tablets (I) have obtained the Pharmaceutical registration certificate.

Gelonghui Finance ·  Dec 10 18:02

On December 10, Guolonghui reported that Zhejiang Huahai Pharmaceutical (600521.SH) announced it has recently received the "Drug Registration Certificate" for Metformin and Empagliflozin Tablets (I) issued by the National Medical Products Administration. The approved product is intended to be used in conjunction with dietary control and exercise for adult patients with type 2 diabetes who are undergoing treatment with Empagliflozin and Metformin hydrochloride, aimed at improving blood sugar control in these patients.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment